BioNTech SE (BNTX) AI Stock Analysis

• Market Cap: $27.04B
• Dividend Yield: N/A
• Average Volume (3M): 789.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 7.51%
• EPS Growth: 30.53%
• Country: US
• Employees: 6,772
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -1.87
• Shares Outstanding: 240,398,730
• 10 Day Avg. Volume: 966,976
• 30 Day Avg. Volume: 789,810
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.37
• Enterprise Value/Revenue: 3.43
• Enterprise Value/Gross Profit: 4.30
• Enterprise Value/Ebitda: -43.41
• 1Y Price Target: $139.44
• Price Target Upside: 23.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17

• Rating: 55 Neutral
• Price Target: $115.00 ▲(2.26% Upside)

BioNTech SE's overall stock score is driven by its strong balance sheet and positive earnings call sentiment, despite profitability and cash flow challenges. Technical indicators show a positive short-term trend, but valuation is impacted by negative earnings. Strategic collaborations and a strong cash position provide a positive outlook, but operational improvements are necessary for long-term stability.

Positive Factors

Financial Guidance

Management reiterated its financial guidance for 2025, which includes total revenues of €1.7-2.2B and indicates confidence in their business strategy.

Litigation Settlement

The patent litigation settlement with CureVac and GSK is incrementally positive, as it removes a litigation headwind and prolonged lawyer fees for BioNTech.

Oncology Developments

BioNTech's BNT327 is positioned to become a future backbone in treating PD-L1 resistant tumors, highlighting its potential impact in oncology.

Negative Factors

Booster Adoption Risks

There are potential risks with US booster adoption and evolving policy shifts, which could impact BioNTech's near-term COVID revenues.

COVID Revenue Decline

Despite the rapid decline in COVID-19 vaccine-related revenues, BioNTech remains a promising opportunity based on its substantial war chest, burgeoning pipeline, and plethora of upcoming data releases.

Enrollment Pause

ROSETTA-LUNG-01 enrollment is temporarily paused, as they assess the Ph 2 dose optimization data and confirm a go-forward dose for the second-stage of the Ph 3 study.

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

How the Company Makes Money

BioNTech generates revenue primarily through the commercialization of its products, particularly its COVID-19 vaccine, which has been a significant source of income due to global demand and government contracts. The company has established key partnerships, notably with Pfizer, which has enabled it to scale production and distribution effectively. In addition to vaccine sales, BioNTech is also involved in research collaborations and licensing agreements, allowing it to earn milestone payments and royalties from its developed therapies. The diversification of its product pipeline, including cancer therapies and other mRNA-based treatments, further contributes to its revenue stream by targeting various therapeutic areas and expanding its market reach.

BioNTech SE Financial Statement Overview

Summary

BioNTech SE shows a mixed financial performance. Despite a strong balance sheet with low leverage, the company faces profitability and cash flow challenges. Revenue growth is evident, but negative net profit margins and deteriorating cash flows are concerning.

Income Statement

BioNTech SE's income statement shows a mixed performance. The company experienced a slight revenue growth of 4.79% in the TTM period, but it is coming off a significant decline from previous years. Gross profit margins remain strong at 79.35%, but net profit margins have turned negative, indicating profitability challenges. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, while revenue is growing, profitability is a concern.

Balance Sheet

The balance sheet of BioNTech SE is relatively strong with a low debt-to-equity ratio of 0.015, indicating low leverage and financial stability. However, the return on equity is negative, reflecting recent losses. The equity ratio is healthy, suggesting a solid capital structure. Despite recent profitability issues, the company's balance sheet remains robust.

Cash Flow

Cash flow analysis reveals challenges for BioNTech SE. The operating cash flow is negative, and free cash flow has significantly deteriorated, although it shows a high free cash flow to net income ratio due to negative net income. The company needs to improve its cash generation capabilities to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.88B	2.75B	3.82B	17.31B	18.98B	482.32M
Gross Profit	2.30B	2.21B	3.22B	12.78B	15.12B	-222.04M
EBITDA	-227.60M	-367.10M	1.09B	12.86B	15.73B	-97.89M
Net Income	-347.44M	-665.30M	930.30M	9.43B	10.29B	15.20M
Balance Sheet
Total Assets	21.64B	22.53B	23.01B	23.28B	15.83B	2.32B
Cash, Cash Equivalents and Short-Term Investments	14.04B	16.78B	16.55B	14.06B	2.07B	1.35B
Total Debt	269.60M	254.20M	219.10M	212.20M	301.50M	240.19M
Total Liabilities	3.13B	3.12B	2.76B	3.22B	3.94B	946.77M
Stockholders Equity	18.51B	19.41B	20.25B	20.06B	11.89B	1.37B
Cash Flow
Free Cash Flow	-2.54B	-244.60M	4.67B	13.21B	735.70M	-98.92M
Operating Cash Flow	-1.72B	207.70M	5.37B	13.58B	889.70M	-13.47M
Investing Cash Flow	1.69B	-2.08B	-6.95B	-35.30M	-566.10M	-144.85M
Financing Cash Flow	-42.30M	-45.90M	-778.60M	-1.42B	94.20M	894.73M

BioNTech SE Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 112.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Positive. The current price of 112.46 is above the 20-day moving average (MA) of 107.98, above the 50-day MA of 109.56, and above the 200-day MA of 108.42, indicating a bullish trend. The MACD of -1.64 indicates Positive momentum. The RSI at 60.10 is Neutral, neither overbought nor oversold. The STOCH value of 42.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTX.

BioNTech SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	82 Outperform	$16.91B	13.64	26.08%	―	23.25%	64.46%
ARGX	74 Outperform	$45.90B	35.27	24.75%	―	89.58%	―
SWTX	61 Neutral		―		―	730.42%	31.63%
ALNY	60 Neutral	$59.25B	―	-257.82%	―	5.01%	-330.09%
BNTX	55 Neutral	$27.04B	―	-1.81%	―	7.51%	30.53%
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
MRNA	48 Neutral	$9.45B	―	-27.50%	―	-38.95%	51.07%